Nabriva Therapeutics

[Nabriva Therapeutics @nabriva]

Today we're celebrating the achievements & spirit of the American Worker. Happy Labor Day! To learn more about the history of Labor Day, visit https://t.co/tBnoTBG9TO.

[Nabriva Therapeutics @nabriva]

@Nabriva Therapeutics presented virtually at the H.C. Wainwright & Co., LLC Global Investment Conference this week. See full presentation located on our website:
https://t.co/rg7xC087DP

[Nabriva Therapeutics @nabriva]

We are excited to announce the extension of our agreement to promote and distribute SIVEXTRO® (tedizolid phosphate) in the U.S. through the end of 2026. Read more here: https://t.co/dbmRgUCpAn

[Nabriva Therapeutics @nabriva]

@nabriva has dosed its first patient in a Phase 1 clinical trial to evaluate the potential of #XENLETA in the management of bacterial infections in patients with cystic fibrosis. Read more here: https://t.co/vZ3c9l10Rq

[Nabriva Therapeutics @nabriva]

Plain Language Summary of #lefamulin Phase III clinical study results now available. Read more here:

[Antimicrobials Working Group @AWG_News]

.@voxdotcom highlights how #AMR is approaching a crisis point while detailing the current market dynamics that styme much needed antimicrobial innovation. Passing the #DISARMAct is a crucial step we can take now to help spur antimicrobial development. https://t.co/aiRslsC4mk

[Nabriva Therapeutics @nabriva]

We are excited to share that our CEO, Ted Schroeder, has been featured in @PharmExec. See below for the full article.

[Pharmaceutical Executive @PharmExec]

🚨Our February issue is LIVE🚨
We're getting ready for #pharma’s next chapter with our CEO #roundtablediscussion 🔷What's up in #biotech these days?🔷A conversation about the ethics of #antibiotics 🔷Plus so much more right here➡️https://t.co/IsYY7kNrXu

#pharma #lifesciences

[Nabriva Therapeutics @nabriva]

@nabriva is a proud member of the @AMRAlliance, working collectively within the life-science industry to combat #AMR.

To learn more about united efforts from all sectors in the pharmaceutical industry, read the #AMRIndustryAlliance Progress Report here:
https://t.co/OvKEjFYAKl

[Biotechnology Innovation Organization @IAmBiotech]

#GoodDayBIO: AMR caused more than 1 million deaths in 2019 – we examine how we can solve that problem. Plus, USDA’s new analysis of the impact of food waste on climate, and Biden’s potential picks to fill retiring Justice Stephen Breyer’s seat. https://t.co/M7TOxm7zWW

[Nabriva Therapeutics @nabriva]

Alarming report published by @TheLancet reveals the magnitude of the #AMR crisis. Study shows #AntimicrobialResistance is a leading cause of death worldwide. Time for action is now. #GRAMpaper

[The Lancet @TheLancet]

NEW—An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections, more deaths than HIV/AIDS or malaria.

#GRAMPaper reveals the scale of antimicrobial resistance (#AMR), now a leading cause of death worldwide: https://t.co/2h5UEKemEq #AMRSOS

[Nabriva Therapeutics @nabriva]

ICYMI: Earlier this week @nabriva provided a business update and preliminary financial results for 4Q 2021. Read more here:https://t.co/9qrAyxxyJ5

[Nabriva Therapeutics @nabriva]

@nabriva to present virtually at the H.C. Wainwright BioConnect 2022 Conference. https://t.co/fFCGrjgVgr

[Nabriva Therapeutics @nabriva]

@nabriva is committed to addressing the global #AMR crisis and strongly supports the advancement of the Pasteur Act to reinforce the urgent need for new antibiotics #pasteuract

[STAT @statnews]

Amid rising concerns over antibiotic resistance, the U.S. Department of Health and Human Services is moving to encourage Congress to create a novel incentive program for drug companies to develop these life-saving medicines. https://t.co/m0MynGLeH1

[Nabriva Therapeutics @nabriva]

It's long past time to sound the alarm on the growing crisis of #antimicrobialresistance. @nabriva is committed to addressing this global crisis and threat to public health. #AntibioticAwarenessWeek

[Antimicrobials Working Group @AWG_News]

#AMR occurs when bacteria, viruses, fungi & parasites change over time and no longer respond to medicines, making infections harder to treat and increasing the risk of death. During #WAAW2021 learn how you can "Spread Awareness, Stop Resistance" https://t.co/CF4tWNdRos

[Nabriva Therapeutics @nabriva]

Join us on November 18th for an on-demand fireside chat with Ted Schroeder, CEO of Nabriva Therapeutics, during the Jefferies London Healthcare Conference, now available here https://t.co/GWkUsp1PTZ #JEFHCLON21

[Nabriva Therapeutics @nabriva]

Our CEO Ted Schroeder is featured in this month’s #LifeScienceLeader discussing his long career in the #antibiotic space, commitment to advancing novel antibiotics to combat #AMR and fixing the flawed stewardship system.

[Nabriva Therapeutics @nabriva]

Today is #WorldPneumoniaDay - over the past two decades Streptococcus pneumoniae, the bacteria most responsible for #CABP, has become increasingly resistant to older classes antibiotics, which is why we are committed to advancing novel antibiotics and stronger stewardship

[AANP @AANP_NEWS]

This #WorldPneumoniaDay, NPs are encouraged to answer the call for #antibioticstewardship to help curb the leading cause of hospitalizations in the U.S. — community-acquired pneumonia. Learn more: https://t.co/8nRvXJj8Kq #NPweek #NPsLead

[Nabriva Therapeutics @nabriva]

ICYMI: A replay of the @nabriva third quarter 2021 financial results webcast is now available: https://t.co/SR8BCmMiTp

[Nabriva Therapeutics @nabriva]

Compelling story reinforcing the urgent need for new antibiotics; Nabriva is committed to addressing the global #AMR crisis by developing innovative #antimicrobial agents with novel mechanisms of action to treat resistant bugs of today and tomorrow

[STAT @statnews]

Opinion: The market for new antibiotics is so broken that even drugs and approaches with more specificity and better safety profiles can't turn a profit, all but destroying incentives for companies to invest in this area. https://t.co/1WHxiUa6Hu

[Nabriva Therapeutics @nabriva]

Nabriva is excited to share a podcast interview with Dr. Thomas File @NEOMEDedu and @SummaHealth on @Consultant360 highlighting a post hoc analysis of LEAP 1 and 2 studies of #lefamulin for treating community-acquired pneumonia presented at @CHEST2021.
https://t.co/SZdd9gsGaW